These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 35084497)

  • 1. Investigation of fluconazole heteroresistance in clinical and environmental isolates of Cryptococcus neoformans complex and Cryptococcus gattii complex in the state of Amazonas, Brazil.
    Moreira IMB; Cortez ACA; de Souza ÉS; Pinheiro SB; de Souza Oliveira JG; Sadahiro A; Cruz KS; Matsuura ABJ; Melhem MSC; Frickmann H; de Souza JVB
    Med Mycol; 2022 Mar; 60(3):. PubMed ID: 35084497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heteroresistance of Cryptococcus gattii to fluconazole.
    Varma A; Kwon-Chung KJ
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2303-11. PubMed ID: 20385871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.
    Sionov E; Chang YC; Garraffo HM; Kwon-Chung KJ
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2804-15. PubMed ID: 19414582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
    Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
    J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.
    Andrade-Silva L; Ferreira-Paim K; Mora DJ; Da Silva PR; Andrade AA; Araujo NE; Pedrosa AL; Silva-Vergara ML
    Med Mycol; 2013 Aug; 51(6):635-40. PubMed ID: 23343452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat.
    Sykes JE; Hodge G; Singapuri A; Yang ML; Gelli A; Thompson GR
    Med Mycol; 2017 Jun; 55(4):396-401. PubMed ID: 28339594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
    Carvajal SK; Melendres J; Escandón P; Firacative C
    Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
    Yang C; Bian Z; Blechert O; Deng F; Chen H; Li Y; Yang Y; Chen M; Zhan P
    Front Cell Infect Microbiol; 2021; 11():723251. PubMed ID: 34790585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
    Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
    Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
    Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
    Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
    Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
    Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.
    Yamazumi T; Pfaller MA; Messer SA; Houston AK; Boyken L; Hollis RJ; Furuta I; Jones RN
    J Clin Microbiol; 2003 Jan; 41(1):267-72. PubMed ID: 12517859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular typing of environmental Cryptococcus neoformans/C. gattii species complex isolates from Manaus, Amazonas, Brazil.
    Alves GS; Freire AK; Bentes Ados S; Pinheiro JF; de Souza JV; Wanke B; Matsuura T; Jackisch-Matsuura AB
    Mycoses; 2016 Aug; 59(8):509-15. PubMed ID: 27005969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E; Vitali LH; Kress MRVZ; Martinez R
    Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal susceptibility of the clinical and environmental strains of Cryptococcus gattii sensu lato in Taiwan.
    Lin KH; Lai YC; Lin YP; Ho MW; Chen YC; Chung WH
    Mycoses; 2023 Jan; 66(1):13-24. PubMed ID: 35986599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
    Lee GA; Arthur I; Merritt A; Leung M
    Med Mycol; 2019 Nov; 57(8):1004-1010. PubMed ID: 30649538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
    Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
    Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.